Comparison of Intralesional Triamcinolone Acetonide Treatment With Intralesional Verapamil Hydrochloride in Keloids

N/ACompletedNCT07420166

Muhammad Aamir Latif60 enrolled

Overview

The paucity of local literature regarding the comparison of intralesional verapamil with intralesional triamcinolone acetonide led this study to be carried out with the objective of comparing the clinical effectiveness of intralesional triamcinolone acetonide and intralesional verapamil hydrochloride in patients with keloids.

Although the anti-inflammatory and scar-enhancing properties of corticosteroids on hypertrophic scars and keloids have been investigated and documented thoroughly. There are many different treatments for keloids nowadays; each method has its advantages and disadvantages, and the results also vary depending on each study. Moreover, local data to address this issue is also scarce. The findings of this study would not add to the existing stats, but comparing the outcomes of both the drugs would also guide clinicians towards better management of keloids by choosing the more appropriate treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Keloid

Interventions

Triamcinolone AcetonideDRUG

Patients received intralesional triamcinolone acetonide (20 mg/ml) at a volume not exceeding 1.5 cc per session every three weeks, for a maximum of eight sessions or until complete scar flattening. Each injection session was preceded by 20 seconds of cryotherapy using cryospray applied at a distance of one centimeter from the lesion.

Verapamil HydrochlorideDRUG

Patients were managed with intralesional verapamil hydrochloride (2.5 mg/ml) at a volume not exceeding 1.5 cc per session every three weeks, for a maximum of eight sessions or until complete scar flattening. Each injection session was preceded by 20 seconds of cryotherapy using cryospray applied at a distance of one centimeter from the lesion.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Either gender * Aged between 20 and 60 years * With keloids * Benign dermal growths * Scar length not exceeding 5 centimeters * Keloid duration of five years or less * A baseline Vancouver Scar Scale score of 5 or more Exclusion Criteria: * Pregnant or lactating women * A family history of keloids * Diagnosed with conditions such as acromegaly, diabetes mellitus, or congestive cardiac disease * a history of thyroidectomy * Current or recent use of isotretinoin or anabolic steroids, as determined by history, physical examination, blood glucose analysis, and electrocardiography

Locations (1)

Bahawal Victoria Hospital/Quaid-e-Azam Medical College

Bahawalpur, Punjab Province, Pakistan

Outcomes

Primary Outcomes

Scar assessment

Using the Vancouver Scar Scale, height, vascularity, pliability, and pigmentation were assessed at baseline and compared with post-treatment measures at 24 weeks. A score closer to 0 was deemed as better vascularity (not red), low pigmentation, high pliability (soft), and low thickness.

Time frame: 24 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.